068760 — Celltrion Pharm Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Celltrion Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	233,568	398,738	386,040	388,794	477,835
Cost of Revenue
Gross Profit	73,164	119,253	112,774	119,710	122,011
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	209,939	350,940	347,870	355,391	440,612
Operating Profit	23,630	47,798	38,170	33,404	37,223
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	20,128	42,522	30,469	26,209	29,759
Provision for Income Taxes
Net Income After Taxes	20,940	34,579	25,960	21,265	21,966
Net Income Before Extraordinary Items
Net Income	20,940	34,579	25,960	21,265	21,966
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	20,940	34,579	25,960	21,265	21,966
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	480	795	596	530	505
Dividends per Share